COVID-19 vaccine antibody responses in community-dwelling adults to 48 weeks post primary vaccine series.
Health sciences
Immune response
Immunology
Microbiology
Public health
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
21 Apr 2023
21 Apr 2023
Historique:
received:
23
12
2022
revised:
16
02
2023
accepted:
22
03
2023
medline:
19
4
2023
pubmed:
19
4
2023
entrez:
19
04
2023
Statut:
ppublish
Résumé
We report a decentralized prospective cohort study of self-reported adverse events and antibody responses to COVID vaccines derived from dried blood spots. Data are presented for 911 older (aged >70 years) and 375 younger (30-50 years) recruits to 48 weeks after the primary vaccine series. After a single vaccine, 83% younger and 45% older participants had overall seropositivity (p < 0.0001) increasing to 100/98% with the second dose, respectively (p = 0.084). A cancer diagnosis (p = 0.009), no mRNA-1273 vaccine doses (p <0 .0001), and older age (p <0 .0001) predicted lower responses. Antibody levels declined in both cohorts at 12 and 24 weeks increasing with booster doses. At 48 weeks, for participants with 3 vaccine doses, the median antibody levels were higher in the older cohort (p = 0.04) with any dose of mRNA-1273 (p <0 .0001) and with COVID infection (p <0 .001). The vaccines were well tolerated. Breakthrough COVID infections were uncommon (16% older cohort, 29% younger cohort; p < 0.0001) and mild
Identifiants
pubmed: 37073374
doi: 10.1016/j.isci.2023.106506
pii: S2589-0042(23)00583-7
pmc: PMC10043971
doi:
Types de publication
Journal Article
Langues
eng
Pagination
106506Informations de copyright
© 2023 The Author(s).
Déclaration de conflit d'intérêts
None of the authors has any financial or other conflicts of interest related to this study. SW has served on advisory boards, spoken at continuing medical education events, and received research funds from ViiV Canada, Glaxo-Smith Kline, Merck, and Gilead pharmaceutical companies.
Références
JAMA. 2021 Oct 12;326(14):1390-1399
pubmed: 34477808
JAMA. 2022 Feb 15;327(7):639-651
pubmed: 35060999
Emerg Infect Dis. 2020 Dec;26(12):2970-2973
pubmed: 32969788
Clin Infect Dis. 2021 Dec 6;73(11):2065-2072
pubmed: 33906236
JAMA. 2021 Oct 19;326(15):1533-1535
pubmed: 34459863
CMAJ. 2022 Dec 5;194(47):E1599-E1609
pubmed: 36507788
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Lancet. 2021 Mar 27;397(10280):1204-1212
pubmed: 33743221
N Engl J Med. 2020 Dec 31;383(27):2684-2686
pubmed: 33326716
Lancet Microbe. 2022 Jan;3(1):e52-e61
pubmed: 34806056
Clin Microbiol Infect. 2022 Jan;28(1):139.e1-139.e4
pubmed: 34508885
N Engl J Med. 2021 Oct 21;385(17):1627-1629
pubmed: 34525276
N Engl J Med. 2014 Aug 14;371(7):635-45
pubmed: 25119609
JAMA. 2022 Oct 11;328(14):1415-1426
pubmed: 36155617
PLoS One. 2020 Aug 14;15(8):e0237833
pubmed: 32797108
Nature. 2021 Aug;596(7872):417-422
pubmed: 34192737
Microbiol Spectr. 2021 Oct 31;9(2):e0017821
pubmed: 34549995
J Infect Dis. 2022 Sep 21;226(6):983-994
pubmed: 35543278
Lancet. 2021 Jun 19;397(10292):2331-2333
pubmed: 34090624
Clin Transl Immunology. 2022 Mar 23;11(3):e1380
pubmed: 35356067
Lancet Infect Dis. 2021 Feb;21(2):e26-e35
pubmed: 33125914
J Am Med Dir Assoc. 2022 Mar;23(3):444-446
pubmed: 35041829
J Infect Dis. 2022 Apr 1;225(7):1129-1140
pubmed: 34888688
JAMA Netw Open. 2022 Sep 1;5(9):e2231334
pubmed: 36098966
N Engl J Med. 2022 Dec 15;387(24):2203-2206
pubmed: 36507702
PLoS One. 2021 Nov 4;16(11):e0258516
pubmed: 34735477
JAMA. 2021 Jun 1;325(21):2201-2202
pubmed: 33818592
JAMA Netw Open. 2021 Sep 1;4(9):e2123622
pubmed: 34473256
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
JAMA Netw Open. 2022 Oct 3;5(10):e2236397
pubmed: 36227594
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
N Engl J Med. 2021 Sep 30;385(14):1330-1332
pubmed: 34469645
Microbiol Spectr. 2022 Apr 27;10(2):e0140521
pubmed: 35266818
Lancet Infect Dis. 2021 Nov;21(11):1474-1475
pubmed: 34174192
Nat Microbiol. 2021 Sep;6(9):1140-1149
pubmed: 34290390
Science. 2022 Jan 07;375(6576):43-50
pubmed: 34812653
Lancet Healthy Longev. 2022 Mar;3(3):e166-e175
pubmed: 35224524
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
JAMA Netw Open. 2022 Jul 1;5(7):e2223096
pubmed: 35862049
N Engl J Med. 2022 May 12;386(19):1804-1816
pubmed: 35263534
N Engl J Med. 2021 Sep 16;385(12):1078-1090
pubmed: 34432976
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
N Engl J Med. 2020 Dec 17;383(25):2427-2438
pubmed: 32991794
N Engl J Med. 2021 Oct 7;385(15):1393-1400
pubmed: 34525275
JAMA. 2021 Jul 21;:
pubmed: 34287620
JAMA Netw Open. 2022 Jul 1;5(7):e2223090
pubmed: 35862048
JAMA Netw Open. 2022 Sep 1;5(9):e2231778
pubmed: 36107426
Sci Immunol. 2020 Oct 8;5(52):
pubmed: 33033173
N Engl J Med. 2021 Sep 9;385(11):1049-1051
pubmed: 34260850
Arch Pathol Lab Med. 2021 Apr 1;145(4):415-418
pubmed: 33264390
N Engl J Med. 2022 Apr 7;386(14):1375-1377
pubmed: 35139265
N Engl J Med. 2022 Jan 13;386(2):116-127
pubmed: 34942067
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Front Immunol. 2022 Nov 14;13:1031852
pubmed: 36451833
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279
Nat Microbiol. 2022 Aug;7(8):1106-1107
pubmed: 35836001
N Engl J Med. 2021 Oct 7;385(15):1355-1371
pubmed: 34496194